ArticleNeuro-oncology advances
Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 9 citations in OpenAlex.
- Post-therapy imaging of adult brain tumours: patterns, pitfalls, and practical framework.Insights into imaging · 2026Article
- Imaging in Neuro-oncology.Seminars in neurology · 2025Review
- EGFR pathway alterations correlate with rapid early progression in glioblastoma.Journal of neuro-oncology · 2025Article
- Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis.Journal of neuro-oncology · 2025Article
- A self-supervised multimodal deep learning approach to differentiate post-radiotherapy progression from pseudoprogression in glioblastoma.Scientific reports · 2025Article
- Improved brain tumor diagnostics and follow-up with novel magnetic resonance imaging methods: A single center study protocol.PloS one · 2025Article
- Contribution of [Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Advances in Neuro-Oncological Imaging: An Update on Diagnostic Approach to Brain Tumors.Cancers · 2024Review
- Article
- Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.Journal of neurosurgery · 2023Review
- Article
- Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay.Cancers · 2023Review
- Contrast clearance analysis in neuro-oncology: A systematic review and meta-analysis on differentiating posttreatment changes from tumor progression.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
Background: There is a need to establish biomarkers that distinguish between pseudoprogression (PsP) and true tumor progression in patients with glioblastoma (GBM) treated with chemoradiation. Methods: We analyzed magnetic resonance spectroscopic imaging (MRSI) and dynamic susceptibility contrast (DSC) MR perfusion data in patients with GBM with PsP or disease progression after chemoradiation. MRSI metabolites of interest included intratumoral choline (Cho), myo-inositol (mI), glutamate + glutamine (Glx), lactate (Lac), and creatine on the contralateral hemisphere (c-Cr). Student Results: 28 subjects (63 ± 9 years, 19 men) were evaluated. Subjects with true progression ( Conclusions: Incorporating enhancing lesion MRSI measures of mI/c-Cr and Lac/Glx into brain tumor imaging protocols can distinguish between PsP and true progression and inform patient management decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.